Formulation Development
Solu Therapeutics Closes $41M Financing & Announces First Patient Dosed in Phase 1 Clinical Trial of STX-0712 in Patients With CMML & Other Advanced Hematologic Malignancies
Solu Therapeutics recently announced the successful completion of a $41 million Series A financing that included participation from five new investors – Eli Lilly and…
CERo Therapeutics Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
CERo Therapeutics Holdings, Inc. recently announced its first clinical trial site for the its Phase 1 clinical trial of CER-1236. The trial is focused on…
Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108
Palisade Bio, Inc. recently announced the completion of enrollment and dosing in all five Phase 1a SAD cohorts, all four MAD cohorts, and the food…
Tolebrutinib Phase 3 Data Demonstrates Benefit on Disability Progression in Multiple Sclerosis
The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with…
Upperton Continues Strategic Growth With the Appointment of Michael Mellor-Clark as Chief Commercial Officer
Upperton Pharma Solutions, a leading UK-based contract development and manufacturing organisation (CDMO), continues its growth following the build of a new sterile manufacturing facility with…
BDD Pharma Opens New GMP Manufacturing Facility
Leading contract research company BDD has opened its new 122m² GMP manufacturing facility at BioCity near Glasgow, following a successful inspection by the Medicines and…
Comanche Biopharma Announces Orphan Drug Designation for CBP-4888 in sFlt1-Mediated Preterm Preeclampsia
Comanche Biopharma Corp. recently announced the European Medicines Agency (EMA) has granted orphan drug designation for CBP-4888 for the treatment of sFlt1-mediated preterm preeclampsia. A…
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
Recursion recently announced that the first patient has been dosed in the Phase 1 EXCELERIZE clinical study evaluating REC-3565 for the treatment of relapsed or…
Opus Genetics Announces 1-Month Clinical Data From Pediatric Patient in Phase 1/2 Trial of Gene Therapy in Inherited Retinal Diseases
Opus Genetics, Inc. recently announced 1-month clinical data from the first pediatric patient treated with its investigational gene therapy, OPGx-LCA5, in a Phase 1/2 open-label…
Sever Announces New Head of Global Business Development & Marketing
Sever Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO) specializing in controlled release systems for highly potent drugs (including Implants, Vaginal Rings and…
Veranova Welcomes Dr. Scott Zugel as Global VP of Analytical Research Development Operations
Veranova is proud to announce the appointment of Dr. Scott Zugel as Global Vice President of Analytical Research Development Operations. Dr. Zugel brings 25 years…
ALX Oncology Receives IND Clearance From FDA for a Novel EGFR-Targeted ADC
ALX Oncology Holdings Inc. recently announced receipt of US FDA clearance for the Investigational New Drug (IND) application for ALX2004, the company’s potential best- and…
Conduit Pharmaceuticals Expands Partnership With Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization
Conduit Pharmaceuticals Inc. recently announced that it has entered into an additional license and use agreement with Sarborg Limited to expand the scope of work…
Ethris & Lonza Collaborate to Develop Spray-Dried mRNA Vaccines for Respiratory Disease Prevention
Ethris and Lonza reecently announced a collaboration to develop room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates, designed for mucosal delivery that offer a promising…
ADC PAYLOADS - Progress in Development of Camptothecin-Based ADC Therapeutics
Paul Moore, PhD, Raffaele Colombo, PhD, and Jamie Rich, PhD, say the recent progress in research on novel camptothecin payloads highlights the potential for developing a new generation of ADCs that can overcome some of the limitations of first-generation therapies.
SPECIAL FEATURE - Bioavailability & Solubility: The Promise of Novel Ingredients
Contributor Cindy H. Dubin, speaks with several innovating companies to discuss the use of novel excipients as well as other methods and technologies for tackling bioavailability and solubility once and for all.
FORMULATION FORUM - Lymphatic versus Portal Drug Delivery: An Understanding of Drug Oral Absorption & Food Effect
Jim Huang, PhD, and Shaukat Ali, PhD, say the lymphatic system is a distinctive route that is essential for drug transport and delivery of large and lipophilic molecules by alleviating the challenges in penetrating blood capillaries.
TREND SCOUTING - Anticipating the Future of Pharma
Gregor Deutschle says by implementing a strategic, considerate, and proactive approach to trend forecasting, pharmaceutical service providers can effectively weigh the benefits and challenges of potential trends, invest in those most aligned with customer needs, and avoid the allocation of time and resources in trends that will not provide meaningful ROI.
DRUG DEVELOPMENT - Improving Bioavailability & Solubility in OSDs
Hibreniguss Terefe, PhD, explores the options available to improve bioavailability and solubility and provides guidance to support decision-making when designing oral formulations for poorly soluble drug candidates in early development.
CELL-FREE GENE SYNTHESIS - Eliminating Critical Bottlenecks in Genetic Medicine Development
Marc Unger explores the market trends, challenges, and opportunities new DNA production technologies provide to accelerate genetic advances in healthcare.
